Cas:383-29-9 4,4′-Sulfonylbis(fluorobenzene) manufacturer & supplier

Chemical Name:4,4′-Sulfonylbis(fluorobenzene)

CAS.NO:383-29-9

Synonyms:Bis(4-fluorophenyl) sulfone;4,4′-Difluorodiphenylsulfone;4,4′-Difluorodiphenyl sulphone;Bis(p-fluorophenyl) sulfone;4,4′-Difluorophenyl sulfone;1-fluoro-4-(4-fluorophenyl)sulfonylbenzene;EINECS 206-847-4;1,1′-Sulfonylbis(4-fluorobenzene);4,4′-Sulfonylbis(fluorobenzene);Sulfone, bis(p-fluorophenyl) (8CI);Benzene, 1,1′-sulfonylbis[4-fluoro-;4,4′-Difluorodiphenyl Sulfone;MFCD00000350;Sulfone, bis(p-fluorophenyl);Bis(4-fluorophenyl)sulfone

Molecular Formula:C₁₂H₈F₂O₂S

Molecular Weight:254.253

HS Code:29309070

Physical and Chemical Properties:

Melting point:98-100 °C(lit.)

Boiling point:368.0±27.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.563

PSA:42.52000

Exact Mass:254.021301

LogP:3.40

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Bis(4-fluorophenyl) sulfone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Bis(4-fluorophenyl)sulfone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 206-847-4 Use and application,4,4′-Difluorodiphenylsulfone technical grade,usp/ep/jp grade.

Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. 4,4′-Sulfonylbis(fluorobenzene) manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 4,4′-Sulfonylbis(fluorobenzene) supplier A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters. 4,4′-Sulfonylbis(fluorobenzene) vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 4,4′-Sulfonylbis(fluorobenzene) factory A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.